

Biocan Novel DHPPI/L4, lyophilisate and suspension for suspension for injection for dogs

1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER

Marketing authorisation holder and
manufacturer responsible for batch release:

Bioveta, a.s.,
Komenského 212/12,
Ivanovice na Hané, 683 23, Czech Republic

2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Biocan Novel DHPPI/L4, lyophilisate and
suspension for suspension for injection for
dogs.

3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

Each dose (1 ml) contains:

Active substances:

Lyophilisate (live attenuated):

	Minimum	Maximum
Canine Distemper virus, strain CDV Bio 11/A	10 ^{5.1} TCID ₅₀ *	10 ^{5.1} TCID ₅₀ *
Canine Adenovirus type 2, strain CAV-2 Bio 13	10 ^{5.3} TCID ₅₀ *	10 ^{5.3} TCID ₅₀ *
Canine Parvovirus type 2b, strain CPV-2b Bio 12/B	10 ^{6.4} TCID ₅₀ *	10 ^{6.4} TCID ₅₀ *
Canine Parainfluenza type 2 virus, strain CPV-2 Bio 15	10 ^{5.1} TCID ₅₀ *	10 ^{5.1} TCID ₅₀ *

Suspension (inactivated):

<i>Leptospira interrogans</i> serogroup Icterohaemorrhagiae	
serovar Icterohaemorrhagiae, strain MSLB 1089	GMT** ≥ 1:51 ALR***
<i>Leptospira interrogans</i> serogroup Canicola serovar Canicola, strain MSLB 1090	GMT** ≥ 1:51 ALR***
<i>Leptospira kirschneri</i> serogroup Grippotyphosa serovar Grippotyphosa, strain MSLB 1091	GMT** ≥ 1:40 ALR***
<i>Leptospira interrogans</i> serogroup Australis serovar Bratislava, strain MSLB 1088	GMT** ≥ 1:51 ALR***

Adjuvant:

Aluminium hydroxide (quantified as Al₂O₃)
1.8 - 2.2 mg

* Tissue culture infectious dose – 50%

** Geometric mean titre

*** Antibody micro agglutination-lytic reaction

The appearance before reconstitution:
Lyophilisate: Spongy matter, white colour.
Suspension: Whitish liquid with easily
shakeable sediments.

4. INDICATION(S)

Active immunization of dogs from six weeks of
age.

- to prevent mortality and clinical signs caused by canine distemper virus
- to prevent mortality and clinical signs caused by canine adenovirus type 1
- to prevent clinical signs and reduce viral excretion caused by canine adenovirus type 2
- to prevent clinical signs, leukopenia and viral excretion caused by canine parvovirus
- to prevent clinical signs (nasal and ocular discharge) and reduce viral excretion caused by canine parainfluenza virus
- to prevent clinical signs, infection and urinary excretion caused by *L. interrogans* serogroup Australis serovar Bratislava
- to prevent clinical signs and urinary excretion and reduce infection caused by *L. interrogans* serogroup Canicola serovar Canicola and *L. interrogans* serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae
- to prevent clinical signs and reduce infection and urinary excretion caused by *L. kirschneri* serogroup Grippotyphosa serovar Grippotyphosa

Onset of immunity:

- 3 weeks after the first dose of the basic vaccination for CDV, CAV, CPV,
- 3 weeks after completion of the basic vaccination for CPV and
- 4 weeks after completion of the basic vaccination for *Leptospira* components.

Duration of immunity:

At least three years following the primary vaccination course for canine distemper virus, canine adenovirus type 1, canine adenovirus type 2 and canine parvovirus. At least one year following the primary vaccination course for canine parainfluenza virus and *Leptospira* components.

The duration of immunity against CAV-2 was not established by challenge. It was shown that 3 years after the vaccination CAV-2 antibodies are still present. Protective immune response against CAV-2 associated respiratory disease is considered to last at least 3 years.

5. CONTRAINDICATIONS

Do not use in case of hypersensitivity to the adjuvant or to any of the excipients.

6. ADVERSE REACTIONS

Following subcutaneous administration in dogs, a small transient swelling (up to 5 cm) may commonly be observed at the injection site, these can occasionally be painful, warm or reddened. Any such swelling will either have spontaneously resolved or be greatly diminished by 14 days after vaccination. In rare cases gastrointestinal signs such as diarrhoea and vomiting or anorexia and decreased activity are possible. As with any vaccine rare, occasional hypersensitivity reactions may occur. If such a reaction occurs, appropriate treatment should be administered without delay.

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon. Alternatively you can report via your national reporting system (national system details).

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

7. TARGET SPECIES

Dogs.

8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

Subcutaneous use.

Basic vaccination scheme:

Two doses of Biocan Novel DHPPI/L4 3-4 weeks apart from 6 weeks of age.

Rabies:

If protection against Rabies is required:

First dose: Biocan Novel DHPPI/L4 from 8-9 weeks of age.

Second dose: Biocan Novel DHPPI/L4R 3-4 weeks later, but not before 12 weeks of age.

The efficacy of the rabies fraction is proven after a single dose from 12 weeks of age in laboratory studies. However, in field studies, 10 % of sero-negative dogs did not show seroconversion (>0.1 IU/ml) 3-4 weeks after single primary vaccination against rabies. Another 17 % did not show the 0.5 IU/ml rabies antibody titre required by some non-EU countries to travel in. In case of travelling to risk areas or for travel outside the EU veterinary surgeons may wish to use a two dose primary course including rabies or give an additional rabies vaccination after 12 weeks. In case of need, dogs younger than 8 weeks can be vaccinated as safety of Biocan Novel DHPPI/L4R has been demonstrated in 6 weeks old dogs.

Revaccination scheme:

A single dose of Biocan Novel DHPPI/L4 should be given every 3 years. Annual revaccination is required for Parainfluenza and Leptospira components, therefore a single dose of compatible vaccine Biocan Novel P/L4 can be used annually as required.

9. ADVICE ON CORRECT ADMINISTRATION

Aseptically reconstitute the lyophilisate with the suspension. Shake well and administer immediately the entire content (1 ml) of the reconstituted product.

Reconstituted vaccine: pinkish or yellowish colour with slight opalescence.

10. WITHDRAWAL PERIOD

Not applicable.

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.

Store and transport refrigerated (2 °C – 8 °C).

Do not freeze. Protect from light.

Do not use after the expiry date which is stated on the label after EXP.

Use immediately after reconstitution.

12. SPECIAL WARNING(S)

Special precautions for use in animals:

The live virus vaccine strains CAV-2, CPV and CPV-2b may be shed by vaccinated dogs but due to the low pathogenicity of the strains, it is not necessary to keep vaccinated dogs separated from non-vaccinated dogs. Since the vaccine virus strain CPV-2b has not been tested in domestic cats and other carnivores (except dogs) that are known to be susceptible to canine parvoviruses, it is recommended vaccinated dogs to be separated from other canine and feline species after vaccination.

Special warnings for each target species:

Immunological responses to the CDV, CAV-2 and CPV components of the vaccine may be August 2019 delayed due to maternally derived antibody interference. However, the vaccine has been proven to be protective against virulent challenge in the presence of maternally derived antibodies to CDV, CAV and CPV at levels equal or higher to those likely to be encountered under field conditions. In situations where very high maternally derived antibodies levels are expected, the vaccination protocol should be planned accordingly. Vaccinate healthy animals only

Pregnancy and lactation:

The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Therefore the use is not recommended during pregnancy and lactation.

Interaction with other medicinal products and other forms of interaction:

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Overdose (symptoms, emergency procedures, antidotes):

No other adverse reactions other than those mentioned in section Adverse reactions were observed after administration of a 10-fold overdose of the vaccine. However in a minority of animals pain was observed at the injection site immediately after administration of a 10-fold overdose of the vaccine. The pain was transient and subsided without requiring any therapy.

Incompatibilities:

Do not mix with any other veterinary medicinal product.

13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

August 2019

15. OTHER INFORMATION

The vaccine is supplied in transparent plastic boxes containing 10, 25 or 50 vials with 1 dose of lyophilisate and 10, 25 or 50 vials with 1 ml (1 dose) of suspension. Not all pack sizes may be marketed.

bioveta